Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering (NARA)

This study has been completed.
Information provided by (Responsible Party):
Yoshihiko Saito, Nara Medical University Identifier:
First received: May 30, 2012
Last updated: October 28, 2013
Last verified: October 2013
The purpose of this study is to compare blood pressure lowering effect of azilsartan with that of valsartan in Japanese patients with hypertension who have already taken normal-dose angiotensin II receptor blockers.

Condition Intervention Phase
Drug: Azilsartan
Drug: Valsartan
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of the New Angiotensin II Receptor Blocker Azilsartan Versus Valsartan on Blood Pressure in Japanese Patients With Hypertension

Resource links provided by NLM:

Further study details as provided by Yoshihiko Saito, Nara Medical University:

Primary Outcome Measures:
  • Change in Office Blood Pressure [ Time Frame: Baseline and every 2 weeks (up to 12 weeks) ]
    Change in blood pressure measured at a clinic

Secondary Outcome Measures:
  • Change in Home Blood Pressure [ Time Frame: Baseline and every 2 weeks (up to 12 weeks) ]

    Change in blood pressure measured at home

    Blood pressure is measured twice daily in the morning fasting before taking any drugs.

  • Change in Renal Function [ Time Frame: Baseline and 12 weeks ]
    Changes in levels of serum creatinine and proteinuria

  • Change in Fasting Triglyceride [ Time Frame: Baseline and 12 weeks ]
  • Change in Glycemic Control [ Time Frame: Baseline and 12 weeks ]
    Changes in levels of fasting blood glucose, hemogrobin A1C and fasting insulin (if needed)

  • Change in Plasma Aldosterone Concentration [ Time Frame: Baseline and 12 weeks ]
    Only in patients with secondary hypertension

Enrollment: 70
Study Start Date: June 2012
Study Completion Date: October 2013
Primary Completion Date: September 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Azilsartan group Drug: Azilsartan
Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
Active Comparator: Valsartan group Drug: Valsartan
Valsartan 160 mg per day

Detailed Description:

Hypertension plays a major role in the development of cardiovascular disease. Several guidelines require strict control of blood pressure for preventing cardiovascular events; however, the control is often poor.

A new angiotensin II receptor blocker (ARB), azilsartan, is the first drug which is superior to other ARBs in blood pressure lowering in phase III clinical trials in Japan. We try to evaluate effect of azilsartan on blood pressure lowering in Japanese patients with hypertension who have already taken normal-dose ARBs, and to compare it with that of valsartan.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hypertensive patients treated with normal-dose angiotensin II receptor blockers (ARBs) in Japan
  • Normal-dose ARBs in Japan are defined as follows: losartan potassium 50 mg, candesartan cilexetil 8 mg, valsartan 80 mg, telmisartan 40 mg, olmesartan medoxomil 20 mg, or irbesartan 100mg per day.

Exclusion Criteria:

  • Hypersensitivity for azilsartan and valsartan
  • Pregnant female
  • History of azilsartan use within 3 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01609959

First Department of Nara Medical University
Kashihara, Nara, Japan, 634-8522
Sponsors and Collaborators
Nara Medical University
Principal Investigator: Yoshihiko Saito, MD, PhD First Department of Internal Medicine, Nara Medical University
  More Information

Responsible Party: Yoshihiko Saito, Professor, Nara Medical University Identifier: NCT01609959     History of Changes
Other Study ID Numbers: 12-Ken-001
Study First Received: May 30, 2012
Last Updated: October 28, 2013

Keywords provided by Yoshihiko Saito, Nara Medical University:
Angiotensin II Receptor Blocker

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Angiotensin Receptor Antagonists
Angiotensin II
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers processed this record on May 25, 2017